Presbyopia is a natural result of aging, and eventually affects all individuals who reach an advanced age. This webinar includes discussions on the shortcomings of current treatments, clinical trial data on the emerging pharmaceutical options for the treatment of presbyopia, and patient selection for these novel therapies.
Supported by an independent medical educational grant from Allergan.
Upon completion of this activity, the participant should be able to:
Evolve Medical Education, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Evolve Medical Education, LLC designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Course Viewing Requirements
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS
Recommended internet speed 5Mbps+
Marjan Farid, MD
Professor of Ophthalmology
School of Medicine
Vice Chair, Ophthalmic Faculty
Director, Cornea/External Disease,
Cataract, and Refractive Surgery
Gavin Herbert Eye Institute
University of California, Irvine
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Francis S. Mah, MD, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant and Speaker’s Bureau:Alcon; Allergan; Bausch + Lomb; Johnson &Johnson Vision; Glaukos; Eyenovia; iView; Nevakar; Novartis; Ocular Science; and RxSight.
Marjan Farid, MD, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Bio-Tissue, CorneaGen, Dompe, Eyepoint, Eyevance, Johnson & Johnson Vision, Kala Pharmaceuticals, Novartis, Orasis, and Zeiss
Daniel H. Chang, MD, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Carl Zeiss Meditec, Johnson & Johnson Vision, Omega Ophthalmics, and Mynosys. Grant/Research Support: Acufocus, Johnson & Johnson Vision, and Mynosys. Shareholder: Omega Ophthalmics.
The Evolve Medical Education staff and planners have no financial relationships with commercial interests.
Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Allergan.